The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1897-1908

  Floris, Giuseppe ^a   Debiec Rychter, Maria ^a   Wozniak, Agnieszka ^a   Stefan, Cristiana ^a   Normant, Emmanuel ^b   Faa, Gavino ^c   Machiels, Kathleen ^a   Vanleeuw, Ulla ^a   Sciot, Raf ^a   Schöffski, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Infinity Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; RETASPIMYCIN; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; HUMAN CELL; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDOLES; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053948974     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0148     Document Type: Article

References (32)

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-41. (Pubitemid 46778870)
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;23:70-83. (Pubitemid 44692418)
3. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25. (Pubitemid 41095223)
4. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8 Suppl 2:1-41.
5. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors after 3 years of treatment: an open-label multicentre randomized phase 3 trial. Lancet Oncol 2010;11:942-9.
6. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohemberger P, van Oosterom AP, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103. (Pubitemid 44275331)
7. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009;15:7510-8.
8. Leigl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase resistance mechanisms in GIST. J Pathol 2008;216:64-74.
9. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72. (Pubitemid 41400776)
10. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7. (Pubitemid 37443877)
11. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113:202-16. (Pubitemid 350015011)
12. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53. (Pubitemid 351429015)
13. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
14. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino- 17demthoxygeldanamycin (17AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004;103:1078-84. (Pubitemid 38129574)
15. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66:9153-61. (Pubitemid 44521135)
16. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vanderberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI- 504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14:5749-58.
17. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, et al. A phase I trial of twice-weekly 17-allylaminodemethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93. (Pubitemid 44703773)
18. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93. (Pubitemid 34517631)
19. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-82. (Pubitemid 46952945)
20. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino- 17-demethoxygeldanamycin hydrochloride), a watersoluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-25. (Pubitemid 40884267)
21. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of HSP90. J Med Chem 2006;49:4606-15. (Pubitemid 44162687)
22. Hanson BE, Vesole DH. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Expert Opin Investig Drugs 2009;18:1375-83.
23. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009;15:4066-76.
24. Rappaport AM. The structural and functional unit in the human liver (liver acinus). Anat Rec 1958;130:673-89.
25. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinibresponsive gastrointestinal stromal tumors. Clin Cancer Res 2007;31:113-20.
26. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DTdiaphorase expression and tumor cell sensitivity to 17-allylamino- 17demthoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
27. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 2003;125:1246-57. (Pubitemid 37193469)
28. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Waldermann E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008;21:476-84. (Pubitemid 351441037)
29. Demetri GD, Le Cesne A, von Mehren M, Chmielowski B, Bauer S, Chow WA, et al. Final results from a phase II study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stroma tumors (GIST) following failure of kinase inhibitor therapies [abstract]. In: Proceedings of the ASCO Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando, FL. Alexandria (VA): ASCO; 2010. Abstract nr 64.
30. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
31. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Wozniak A, Machiels K, et al. Efficacy of IPI-504 'a novel inhibitor of heat shock protein 90′ in a preclinical mouse model of gastrointestinal stromal tumor (GIST) [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 April 18-23; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4692.
32. Schöffski P, Floris G, Sciot R, Stefan C, Wozniak A, Machiels K, et al. Assessment of the heat shock protein 90 (HSP90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of human gastrointestinal stromal tumors (GIST). Proceedings of the ASCO Annual Meeting. J Clin Oncol 2009;27 Suppl:15S:10534.